Adalat

Anal sphincter hypertonia, Proctalgia, Altitude Sickness + 12 more
Treatment
3 FDA approvals
20 Active Studies for Adalat

What is Adalat

NifedipineThe Generic name of this drug
Treatment SummaryNifedipine (brand name BAY a 1040) is a type of medication used to treat high blood pressure. It belongs to a class of drugs known as calcium channel blockers and is the first of its kind to be developed. Nifedipine works by blocking calcium from entering the cells in the walls of arteries, which reduces tension and widens them. This helps to lower blood pressure and improve blood flow. There are newer, second and third generation versions of nifedipine with slower onset times and longer-lasting effects, such as amlodipine. Nifedipine was approved by
Procardiais the brand name
image of different drug pills on a surface
Adalat Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Procardia
Nifedipine
1981
355

Approved as Treatment by the FDA

Nifedipine, otherwise called Procardia, is approved by the FDA for 3 uses like Angina, Stable and Failed conventional therapy .
Angina, Stable
Helps manage Chronic Stable Angina Pectoris
Failed conventional therapy
Helps manage Failed conventional therapy
Vasospastic Angina
Helps manage Vasospastic Angina

Effectiveness

How Adalat Affects PatientsNifedipine is a medication that helps to lower blood pressure and increase the amount of oxygen that reaches the heart. It needs to be taken three times a day, typically in doses of 10 to 120mg daily. It is important for patients to be aware of the risks associated with taking this medication, such as excessively low blood pressure, chest pain and heart attack.
How Adalat works in the bodyNifedipine helps reduce blood pressure and ease chest pain by blocking the entry of calcium ions into cells. This stops the cells from becoming over-stimulated, allowing blood vessels to relax and provide more oxygen to the heart.

When to interrupt dosage

The suggested dose of Adalat is contingent upon the diagnosed condition, including Achalasia, Ureteral Calculus and Hypertensive disease. The amount of dosage varies, as per the method of delivery (e.g. Tablet, film coated, extended release or Capsule) specified in the table below.
Condition
Dosage
Administration
Ureteral Calculi
30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL
Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release, Capsule
Fissure in Ano
30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL
Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release, Capsule
Angina, Stable
30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL
Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release, Capsule
Vasospastic Angina
30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL
Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release, Capsule
Failed conventional therapy
30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL
Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release, Capsule
Proctalgia
30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL
Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release, Capsule
Pulmonary Edema
30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL
Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release, Capsule
Altitude Sickness
30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL
Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release, Capsule
Raynaud Disease
30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL
Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release, Capsule
Hypertensive disease
30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL
Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release, Capsule
Hypertensive Emergency
30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL
Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release, Capsule
Anal sphincter hypertonia
30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL
Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release, Capsule
Obstetric Labor, Premature
30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL
Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release, Capsule
Esophageal Achalasia
30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL
Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release, Capsule
Pulmonary Hypertension
30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL
Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release, Capsule

Warnings

Adalat has one contraindication, thus its use should be avoided if any of the situations in the table below are present.Adalat Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Nifedipine may interact with Pulse Frequency
There are 20 known major drug interactions with Adalat.
Common Adalat Drug Interactions
Drug Name
Risk Level
Description
Amitriptyline
Major
The metabolism of Amitriptyline can be decreased when combined with Nifedipine.
Amoxapine
Major
The metabolism of Amoxapine can be decreased when combined with Nifedipine.
Anagrelide
Major
The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Anagrelide.
Arsenic trioxide
Major
The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Arsenic trioxide.
Artemether
Major
The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Artemether.
Adalat Toxicity & Overdose RiskThe lowest toxic dose of the drug in rats was found to be 1022mg/kg and in mice was 202mg/kg. An overdose on this drug may cause low blood pressure, problems with the heart rate, and rapid heartbeat. Treatment for an overdose should involve monitoring vital signs, raising the patient's extremities, and administering fluids, vasopressors, and calcium.
image of a doctor in a lab doing drug, clinical research

Adalat Novel Uses: Which Conditions Have a Clinical Trial Featuring Adalat?

101 active investigations are exploring the potential of Adalat to mitigate Achalasia, Hypertensive Emergency and Anal Fissures.
Condition
Clinical Trials
Trial Phases
Obstetric Labor, Premature
2 Actively Recruiting
Not Applicable
Pulmonary Edema
0 Actively Recruiting
Hypertensive disease
28 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
Angina, Stable
0 Actively Recruiting
Esophageal Achalasia
0 Actively Recruiting
Altitude Sickness
0 Actively Recruiting
Raynaud Disease
1 Actively Recruiting
Phase 4
Pulmonary Hypertension
31 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1
Proctalgia
0 Actively Recruiting
Hypertensive Emergency
1 Actively Recruiting
Phase 4
Fissure in Ano
0 Actively Recruiting
Vasospastic Angina
1 Actively Recruiting
Phase 2, Phase 3
Anal sphincter hypertonia
0 Actively Recruiting
Ureteral Calculi
0 Actively Recruiting
Failed conventional therapy
0 Actively Recruiting

Adalat Reviews: What are patients saying about Adalat?

5Patient Review
11/13/2007
Adalat for Angina
3Patient Review
1/16/2008
Adalat for Angina
My blood pressure and chest pain are much more manageable now.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about adalat

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is nifedipine and Adalat the same thing?

"Nifedipine is available as an oral tablet in the brand-name drugs Adalat CC, Afeditab CR, and Procardia XL. These are all extended-release tablets, meaning the drug is slowly released into your bloodstream over time."

Answered by AI

When do you give Adalat?

"It is recommended that you take Adalat CC once a day on an empty stomach. Adalat CC is an extended release dosage form, which means you should swallow the tablet whole, without biting or dividing it. In general, you should start with 30 mg once a day, and increase the dosage over a 7-14 day period."

Answered by AI

Is Adalat for blood pressure?

"Nifedipine, sold under the brand name Adalat, is a calcium channel blocker used to lower high blood pressure and treat chest pain. Nifedipine slows the movement of calcium into the cells of the heart and blood vessels. This relaxes the blood vessels, lowers blood pressure, and makes it easier for the heart to pump."

Answered by AI

What is Adalat used for?

"This medication prevents certain types of chest pain by blocking calcium channels. This allows the individual to exercise more and have fewer angina attacks."

Answered by AI

Clinical Trials for Adalat

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL
This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.
Waitlist Available
Has No Placebo
U Health (+1 Sites)Ziad Zoghby, M.D., M.B.A.Biobeat Technologies Ltd.
Image of UPMC Presybeterian in Pittsburgh, United States.

Telaglenastat for Pulmonary Hypertension

18 - 75
All Sexes
Pittsburgh, PA
The research study is being conducted to evaluate the effectiveness of a drug called Telaglenastat in adults diagnosed with Pulmonary Hypertension (PH). PH is a progressive condition that affects the arteries in the lungs, specifically the pulmonary arteries, which carry blood from the right side of the heart to the lungs. Telaglenastat is not currently approved by the Food and Drug Administration for the treatment of PH. However, the study investigators believe that Telaglenastat may help lower blood pressure in the lungs and improve both heart and lung function. It is important to note that the drug will not be available to participants once the study concludes.
Phase 1 & 2
Waitlist Available
UPMC PresybeterianMichael Risbano, MD
Have you considered Adalat clinical trials? We made a collection of clinical trials featuring Adalat, we think they might fit your search criteria.Go to Trials
Image of University of Alabama at Birmingham in Birmingham, United States.

Dietary Interventions for Hypertension

18+
All Sexes
Birmingham, AL
Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.
Waitlist Available
Has No Placebo
University of Alabama at BirminghamPankaj Arora, MD, FAHA
Image of Brigham and Women's Hospital in Boston, United States.

Oral Treprostinil for Raynaud's Disease

18+
All Sexes
Boston, MA
Raynaud's phenomenon is a condition where the blood vessels in participants fingers and toes get too narrow when cold or stressed. This makes participants fingers and toes change colors - they might turn white, then blue, and finally red as blood flow returns. It can be painful and cause numbness or tingling. When participants have Raynaud's, blood vessels react too strongly to cold or stress. Fingers and toes may turn white (blood moves away from the area), blue (lack of oxygen), or red and feel painful or tingly when warming up. These episodes usually last from a few minutes to several hours. There are two types of Raynaud's. Primary Raynaud's (also called Raynaud's disease) itself and isn't connected to other health problems. It's the most common type and affects mostly women under 30. Secondary Raynaud's (also called Raynaud's phenomenon) is caused by other diseases like lupus, scleroderma, or rheumatoid arthritis. This type tends to be more serious and may cause painful sores on fingertips called digital ulcers. For mild cases, staying warm might be enough. But if symptoms are severe, participants doctor might prescribe various medications including calcium channel blockers - blood pressure medicines that help open blood vessels, or other vasodilators - medicines that widen blood vessels. About 40% of people with scleroderma develop painful sores on their fingertips called digital ulcers. These happen when there isn't enough blood flow to heal small injuries. For severe cases with digital ulcers, doctors might use prostacyclin therapy - medicines that mimic a natural substance that opens blood vessels. Oral treprostinil is a newer pill form of prostacyclin therapy that helps improve blood flow. The investigators are conducting a research study testing whether oral treprostinil - a pill that mimics prostacyclin (a natural blood vessel opener) - can help people with severe Raynaud's that doesn't respond to usual treatments. This represents hope for better treatment options for people with the most challenging cases of this condition.
Phase 4
Waitlist Available
Brigham and Women's HospitalAaron B Waxman, MD, PhD
Have you considered Adalat clinical trials? We made a collection of clinical trials featuring Adalat, we think they might fit your search criteria.Go to Trials
Image of University of Oklahoma health sciences Center in Oklahoma City, United States.

Neuromodulation for Pulmonary Arterial Hypertension

18 - 90
All Sexes
Oklahoma City, OK
Patients with Group 1 pulmonary hypertension will be enrolled in this study. Investigators will test the hypothesis of low-level tragal stimulation in patients with pulmonary hypertension. The study will be conducted over 4 weeks and patients will undergo low-level tragus stimulation for 1 hour every day for 4 weeks. At baseline the following tests will be conducted-6-minute walk distance, vascular function testing using noninvasive device and blood samples will be collected. Patient will also undergo a limited echocardiography to assess right ventricular function. After 4 weeks of stimulation patients will come back to undergo these tests again. Investigators hypothesized that low-level tragus stimulation (neuromodulation) will lead to improvement in vascular function, 6-minute walk distance and blood based biomarkers in patients with pulmonary hypertension.
Phase 1 & 2
Waitlist Available
University of Oklahoma health sciences CenterTarun Dasari, MD
Have you considered Adalat clinical trials? We made a collection of clinical trials featuring Adalat, we think they might fit your search criteria.Go to Trials